Polymyxins Revisited
暂无分享,去创建一个
John Quale | David Landman | D. Landman | C. Georgescu | D. Martin | J. Quale | Claudiu Georgescu | Don Antonio Martin
[1] N. Høiby,et al. Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment , 1991, The Lancet.
[2] D. Landman,et al. Carbapenemase-producing Klebsiella pneumoniae in Brooklyn, NY: molecular epidemiology and in vitro activity of polymyxin B and other agents. , 2005, The Journal of antimicrobial chemotherapy.
[3] E. Federman,et al. Adverse effects of sodium colistimethate. Manifestations and specific reaction rates during 317 courses of therapy. , 1970, Annals of internal medicine.
[4] S. Segal-Maurer,et al. Successful treatment of ceftazidime-resistant Klebsiella pneumoniae ventriculitis with intravenous meropenem and intraventricular polymyxin B: case report and review. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[5] J. Barr,et al. In-vitro activity of the combination of colistin and rifampicin against multidrug-resistant strains of Acinetobacter baumannii. , 1998, The Journal of antimicrobial chemotherapy.
[6] C. Cabellos,et al. Efficacy of Colistin versus β-Lactams, Aminoglycosides, and Rifampin as Monotherapy in a Mouse Model of Pneumonia Caused by Multiresistant Acinetobacter baumannii , 2002, Antimicrobial Agents and Chemotherapy.
[7] R. Wise,et al. A reassessment of the in-vitro activity of colistin sulphomethate sodium. , 1997, The Journal of antimicrobial chemotherapy.
[8] E. Wolinsky,et al. Neurotoxic and nephrotoxic effects of colistin in patients with renal disease. , 1962, The New England journal of medicine.
[9] E. Giamarellos‐Bourboulis,et al. In Vitro Interaction of Colistin and Rifampin on Multidrug-Resistant Pseudomonas aeruginosa , 2003, Journal of chemotherapy.
[10] J. Turnidge,et al. Subacute Toxicity of Colistin Methanesulfonate in Rats: Comparison of Various Intravenous Dosage Regimens , 2008, Antimicrobial Agents and Chemotherapy.
[11] J. Wynne,et al. Passage of chloramphenicol and sodium colistimethate into the cerebrospinal fluid. Studies of hydrocephalic children. , 1966, American journal of diseases of children.
[12] J. Turnidge,et al. A simple method for the assay of colistin in human plasma, using pre-column derivatization with 9-fluorenylmethyl chloroformate in solid-phase extraction cartridges and reversed-phase high-performance liquid chromatography. , 2001, Journal of chromatography. B, Biomedical sciences and applications.
[13] T. Petty,et al. Reversible respiratory paralysis associated with polymyxin therapy. , 1969, Annals of internal medicine.
[14] W. E. Wellman,et al. Pseudomonas meningitis: report of a case. , 1960, The Medical clinics of North America.
[15] A. Armaganidis,et al. Colistin-resistant isolates of Klebsiella pneumoniae emerging in intensive care unit patients: first report of a multiclonal cluster. , 2007, The Journal of antimicrobial chemotherapy.
[16] M. Cutler,et al. Pseudomonas meningitis. , 1953, American practitioner and digest of treatment.
[17] W. Gump,et al. Intrathecal colistin for treatment of highly resistant Pseudomonas ventriculitis. Case report and review of the literature. , 2005, Journal of neurosurgery.
[18] A. Levin,et al. Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[19] D. Kaye,et al. SERUM CONCENTRATIONS OF COLISTIN IN PATIENTS WITH NORMAL AND IMPAIRED RENAL FUNCTION. , 1964, The New England journal of medicine.
[20] Jian Li,et al. Pharmacokinetics of Colistin Methanesulfonate and Colistin in a Critically Ill Patient Receiving Continuous Venovenous Hemodiafiltration , 2005, Antimicrobial Agents and Chemotherapy.
[21] J. Pachón,et al. Reliability of the E-Test Method for Detection of Colistin Resistance in Clinical Isolates of Acinetobacter baumannii , 2005, Journal of Clinical Microbiology.
[22] D. Landman,et al. Citywide emergence of Pseudomonas aeruginosa strains with reduced susceptibility to polymyxin B. , 2005, The Journal of antimicrobial chemotherapy.
[23] John Quale,et al. Emergence of KPC-Possessing Klebsiella pneumoniae in Brooklyn, New York: Epidemiology and Recommendations for Detection , 2005, Antimicrobial Agents and Chemotherapy.
[24] X. Corbella,et al. Successful treatment of ventriculitis due to carbapenem-resistant Acinetobacter baumannii with intraventricular colistin sulfomethate sodium. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[25] R. S. Conrad,et al. Conversion of phospholipids to free fatty acids in response to acquisition of polymyxin resistance in Pseudomonas aeruginosa , 1983, Antimicrobial Agents and Chemotherapy.
[26] S. Conway,et al. Intravenous colistin sulphomethate in acute respiratory exacerbations in adult patients with cystic fibrosis. , 1997, Thorax.
[27] M. Falagas,et al. Outcome of infections due to pandrug-resistant (PDR) Gram-negative bacteria , 2005, BMC infectious diseases.
[28] S. Cunningham,et al. Bronchoconstriction following nebulised colistin in cystic fibrosis , 2001, Archives of disease in childhood.
[29] J. Turnidge,et al. In Vitro Pharmacodynamic Properties of Colistin and Colistin Methanesulfonate against Pseudomonas aeruginosaIsolates from Patients with Cystic Fibrosis , 2001, Antimicrobial Agents and Chemotherapy.
[30] J. Turnidge,et al. Simple Method for Assaying Colistin Methanesulfonate in Plasma and Urine Using High-Performance Liquid Chromatography , 2002, Antimicrobial Agents and Chemotherapy.
[31] M. Badia,et al. Use of colistin in the treatment of multiple-drug-resistant gram-negative infections. , 2005, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[32] S. Fesik,et al. Decreased binding of antibiotics to lipopolysaccharides from polymyxin-resistant strains of Escherichia coli and Salmonella typhimurium , 1987, Antimicrobial Agents and Chemotherapy.
[33] E. Friedman,et al. The effects of renal impairment, peritoneal dialysis, and hemodialysis on serum sodium colistimethate levels. , 1968, Annals of internal medicine.
[34] R. Nation,et al. Antibiograms of multidrug-resistant clinical Acinetobacter baumannii: promising therapeutic options for treatment of infection with colistin-resistant strains. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[35] J. Turnidge,et al. Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria. , 2005, International journal of antimicrobial agents.
[36] H. Cheong,et al. In vitro activities of carbapenem/sulbactam combination, colistin, colistin/rifampicin combination and tigecycline against carbapenem-resistant Acinetobacter baumannii. , 2007, The Journal of antimicrobial chemotherapy.
[37] H. E. Gilleland,et al. Adaptive resistance to polymyxin in Pseudomonas aeruginosa due to an outer membrane impermeability mechanism. , 1982, Canadian journal of microbiology.
[38] R. G. Benedict,et al. Antibiotic activity of Bacillus polymyxa. , 1947, Journal of bacteriology.
[39] M. Finland,et al. POLYMYXIN B AND COLISTIN: IN VITRO ACTIVITY AGAINST PSEUDOMONAS AERUGINOSA. , 1965, The American journal of the medical sciences.
[40] M. Falagas,et al. The use of intravenous and aerosolized polymyxins for the treatment of infections in critically ill patients: a review of the recent literature. , 2006, Clinical medicine & research.
[41] G. Stewart,et al. Intraventricular administration of a new derivative of polymyxin B in meningitis due to Ps. pyocyanea. , 1961, Lancet.
[42] M. Rocchi,et al. Efficacy of colistin/rifampin combination in experimental rat models of sepsis due to a multiresistant Pseudomonas aeruginosa strain* , 2007, Critical care medicine.
[43] C. Kunin. A guide to use of antibiotics in patients with renal disease. A table of recommended doses and factors governing serum levels. , 1967, Annals of internal medicine.
[44] S. Curatola,et al. Serum and urine levels following parenteral administration of sodium colistimethate to normal individuals. , 1970, The Journal of urology.
[45] R. Muehrcke,et al. Acute renal failure associated with sodium colistimethate treatment. , 1966, Archives of internal medicine.
[46] A. Vicente,et al. Coexistence of epidemic colistin-only-sensitive clones of Pseudomonas aeruginosa, including the blaSPM clone, spread in hospitals in a Brazilian Amazon City. , 2007, Microbial drug resistance.
[47] F. Barkley,et al. Microbiological and pharmacological studies of colistin sulfate and sodium colistinmethanesulfonate. , 1959, Antibiotics annual.
[48] Phillip J. Bergen,et al. Colistin Methanesulfonate Is an Inactive Prodrug of Colistin against Pseudomonas aeruginosa , 2006, Antimicrobial Agents and Chemotherapy.
[49] C. Kunin,et al. Binding of polymyxin antibiotics to tissues: the major determinant of distribution and persistence in the body. , 1971, The Journal of infectious diseases.
[50] H. White,et al. Polymyxin: a new chemotherapeutic agent. , 1947, Bulletin of the Johns Hopkins Hospital.
[51] E. Estenssoro,et al. Safety and efficacy of colistin in Acinetobacter and Pseudomonas infections: a prospective cohort study , 2005, Intensive Care Medicine.
[52] E. Yow,et al. MENINGITIS DUE TO PSEUDOMONAS AERUGINOSA TREATED WITH POLYMYXIN B , 1950, The American journal of the medical sciences.
[53] Matthew E Falagas,et al. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[54] J. Pachón,et al. Successful Treatment of Multidrug-Resistant Acinetobacter baumannii Meningitis with Intravenous Colistin Sulfomethate Sodium , 2000, European Journal of Clinical Microbiology and Infectious Diseases.
[55] C. Cabellos,et al. Antibiotic combinations for serious infections caused by carbapenem-resistant Acinetobacter baumannii in a mouse pneumonia model. , 2004, The Journal of antimicrobial chemotherapy.
[56] G. Wortmann,et al. In vitro activity of colistin against multidrug-resistant gram-negative bacteria isolated at a major army hospital during the military campaigns in Iraq and Afghanistan. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[57] J. Parada,et al. Intrathecal Colistin and Sterilization of Resistant Pseudomonas Aeruginosa Shunt Infection , 2005, The Annals of pharmacotherapy.
[58] R. Jones,et al. Global assessment of the antimicrobial activity of polymyxin B against 54 731 clinical isolates of Gram-negative bacilli: report from the SENTRY antimicrobial surveillance programme (2001-2004). , 2006, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[59] I. Kilpeläinen,et al. Lipopolysaccharides of polymyxin B‐resistant mutants of Escherichia coii are extensively substituted by 2‐aminoethyl pyrophosphate and contain aminoarabinose in lipid A , 1995, Molecular microbiology.
[60] Jian Li,et al. Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review. , 2007, The Journal of antimicrobial chemotherapy.
[61] Ronald N. Jones,et al. Antimicrobial Activities of Tigecycline and Other Broad-Spectrum Antimicrobials Tested against Serine Carbapenemase- and Metallo-β-Lactamase-Producing Enterobacteriaceae: Report from the SENTRY Antimicrobial Surveillance Program , 2007, Antimicrobial Agents and Chemotherapy.
[62] Russell E. Lewis,et al. Pharmacodynamics of Polymyxin B against Pseudomonas aeruginosa , 2005, Antimicrobial Agents and Chemotherapy.
[63] Clinical,et al. Performance standard for antimicrobial susceptibility testing. , 2010 .
[64] F. Hinman,et al. POLYMYXIN B IN CHRONIC PYELONEPHRITIS: OBSERVATIONS ON THE SAFETY OF THE DRUG AND ON ITS INFLUENCE ON THE RENAL INFECTION , 1953, The American journal of the medical sciences.
[65] T. Schülin. In vitro activity of the aerosolized agents colistin and tobramycin and five intravenous agents against Pseudomonas aeruginosa isolated from cystic fibrosis patients in southwestern Germany. , 2002, The Journal of antimicrobial chemotherapy.
[66] Ronald N. Jones,et al. Contemporary Assessment of Antimicrobial Susceptibility Testing Methods for Polymyxin B and Colistin: Review of Available Interpretative Criteria and Quality Control Guidelines , 2001, Journal of Clinical Microbiology.
[67] T. Tan,et al. In vitro effect of minocycline and colistin combinations on imipenem-resistant Acinetobacter baumannii clinical isolates. , 2007, The Journal of antimicrobial chemotherapy.
[68] T. Tsaganos,et al. Colistin offers prolonged survival in experimental infection by multidrug-resistant Acinetobacter baumannii: the significance of co-administration of rifampicin. , 2007, International journal of antimicrobial agents.
[69] D. Trapnell. Pseudomonas pyocyanea meningitis successfully treated with polymyxin. , 1954, Lancet.
[70] R. S. Conrad,et al. Fatty acid alterations and polymyxin B binding by lipopolysaccharides from Pseudomonas aeruginosa adapted to polymyxin B resistance , 1989, Antimicrobial Agents and Chemotherapy.
[71] F. Can,et al. In vitro activities of non-traditional antimicrobials alone or in combination against multidrug-resistant strains of Pseudomonas aeruginosa and Acinetobacter baumannii isolated from intensive care units. , 2006, International journal of antimicrobial agents.
[72] D. Landman,et al. Endemic carbapenem-resistant Acinetobacter species in Brooklyn, New York: citywide prevalence, interinstitutional spread, and relation to antibiotic usage. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[73] M. Benifla,et al. Successful treatment of Acinetobacter meningitis with intrathecal polymyxin E. , 2004, The Journal of antimicrobial chemotherapy.
[74] H. S. Warren,et al. Binding and neutralization of bacterial lipopolysaccharide by colistin nonapeptide , 1985, Antimicrobial Agents and Chemotherapy.
[75] D. Raoult,et al. Colistin: an antimicrobial for the 21st century? , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[76] P. N. Swift,et al. Haemophilus influenza meningitis treated with polymyxin. , 1951, Lancet.
[77] E. Groisman,et al. Regulation of polymyxin resistance and adaptation to low-Mg2+ environments , 1997, Journal of bacteriology.
[78] D. Rifkind. Prevention by polymyxin B of endotoxin lethality in mice , 1967, Journal of bacteriology.
[79] M. Walshaw,et al. Four years' experience of intravenous colomycin in an adult cystic fibrosis unit. , 1998, The European respiratory journal.
[80] E. Rietschel,et al. Chemical structure of the lipid A component of the lipopolysaccharide from a Proteus mirabilis Re-mutant. , 1983, European journal of biochemistry.
[81] C. Tascini,et al. Microbiological Activity and Clinical Efficacy of a Colistin and Rifampin Combination in Multidrug-Resistant Pseudomonas aeruginosa Infections , 2004, Journal of chemotherapy.
[82] D. Feola,et al. Polymyxin B Sulfate and Colistin: Old Antibiotics for Emerging Multiresistant Gram-Negative Bacteria , 1999, The Annals of pharmacotherapy.
[83] D. Paterson,et al. Use of parenteral colistin for the treatment of serious infection due to antimicrobial-resistant Pseudomonas aeruginosa. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[84] E. Jawetz,et al. Infections of the central nervous system due to pseudomonas aeruginosa. , 1969, Journal of neurosurgery.
[85] T. Tan,et al. Susceptibility testing of unconventional antibiotics against multiresistant Acinetobacter spp. by agar dilution and Vitek 2. , 2007, Diagnostic microbiology and infectious disease.
[86] P. Hoeprich,et al. POLYMYXIN B AND COLISTIN. A CRITICAL COMPARISON. , 1964, The New England journal of medicine.
[87] M. Spector,et al. Starvation- and Stationary-phase-induced resistance to the antimicrobial peptide polymyxin B in Salmonella typhimurium is RpoS (sigma(S)) independent and occurs through both phoP-dependent and -independent pathways , 1996, Journal of bacteriology.
[88] A. Gales,et al. Polymyxin-Resistant Acinetobacter spp. Isolates: What is Next? , 2003, Emerging infectious diseases.
[89] S. Korfias,et al. Successful treatment of multidrug-resistant Pseudomonas aeruginosa meningitis with intravenous and intrathecal colistin. , 2006, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.
[90] M. Kitzis,et al. Comparison of Etest with agar dilution for testing the susceptibility of Pseudomonas aeruginosa and other multidrug-resistant bacteria to colistin. , 2007, The Journal of antimicrobial chemotherapy.
[91] D. Landman,et al. Evolution of antimicrobial resistance among Pseudomonas aeruginosa, Acinetobacter baumannii and Klebsiella pneumoniae in Brooklyn, NY. , 2007, The Journal of antimicrobial chemotherapy.
[92] J. Pachón,et al. Colistin efficacy in an experimental model of Acinetobacter baumannii endocarditis. , 2004, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[93] A. Coates,et al. Bronchial constriction and inhaled colistin in cystic fibrosis. , 2005, Chest.
[94] T. Tan,et al. Comparison of Etest, Vitek and agar dilution for susceptibility testing of colistin. , 2007, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[95] C. Urban,et al. In Vitro Double and Triple Synergistic Activities of Polymyxin B, Imipenem, and Rifampin against Multidrug-Resistant Acinetobacter baumannii , 2004, Antimicrobial Agents and Chemotherapy.
[96] M. Finland,et al. Polymyxin B and Colistin , 1960, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.
[97] Ronald N. Jones,et al. CANCER Resistance Surveillance Program: Initial Results from Hematology–Oncology Centers in North America , 2003, The Annals of pharmacotherapy.
[98] M. Falagas,et al. Toxicity after prolonged (more than four weeks) administration of intravenous colistin , 2005, BMC infectious diseases.
[99] M. Athanasiou,et al. Intravenous colistin in the treatment of sepsis from multiresistant Gram-negative bacilli in critically ill patients , 2003, Critical care.
[100] A. Karabinis,et al. Colistin for Klebsiella pneumoniae-associated sepsis. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[101] E. Giamarellos‐Bourboulis,et al. Synergy of colistin with rifampin and trimethoprim/sulfamethoxazole on multidrug-resistant Stenotrophomonas maltophilia. , 2002, Diagnostic microbiology and infectious disease.
[102] D. Landman,et al. Multidrug-resistant Pseudomonas aeruginosa in Brooklyn, New York: molecular epidemiology and in vitro activity of polymyxin B , 2005, European Journal of Clinical Microbiology and Infectious Diseases.
[103] J. Pachón,et al. Cerebrospinal Fluid Penetration and Pharmacokinetic/Pharmacodynamic Parameters of Intravenously Administered Colistin in a Case of Multidrug-Resistant Acinetobacter baumannii Meningitis , 2002, European Journal of Clinical Microbiology and Infectious Diseases.
[104] J. E. Eiros Bouza,et al. Susceptibility of the Acinetobacter calcoaceticus-A. baumannii complex to imipenem, meropenem, sulbactam and colistin. , 2004, International journal of antimicrobial agents.
[105] F. Bistoni,et al. Evaluation of the activities of two-drug combinations of rifampicin, polymyxin B and ampicillin/sulbactam against Acinetobacter baumannii. , 1998, The Journal of antimicrobial chemotherapy.
[106] E. Nicastri,et al. Combined colistin and rifampicin therapy for carbapenem-resistant Acinetobacter baumannii infections: clinical outcome and adverse events. , 2005, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[107] T. Tan,et al. Comparison of three standardized disc susceptibility testing methods for colistin. , 2006, The Journal of antimicrobial chemotherapy.
[108] J. Li,et al. In vitro pharmacodynamics of colistin against Acinetobacter baumannii clinical isolates. , 2007, The Journal of antimicrobial chemotherapy.
[109] C. Luna,et al. Ventilator-associated pneumonia due to colistin susceptible-only microorganisms , 2007, European Respiratory Journal.
[110] T. Yokochi,et al. Characterization of lipopolysaccharides of polymyxin-resistant and polymyxin-sensitive Klebsiella pneumoniae O3. , 1996, European journal of biochemistry.
[111] John Quale,et al. Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York City: a new threat to our antibiotic armamentarium. , 2005, Archives of internal medicine.
[112] P. Norman,et al. The treatment of gram-negative bacillary infections with colistin. The toxicity and efficacy of large doses in forty-eight patients. , 1962, Annals of internal medicine.
[113] J. Kluytmans,et al. Comparative Evaluation of the VITEK 2, Disk Diffusion, Etest, Broth Microdilution, and Agar Dilution Susceptibility Testing Methods for Colistin in Clinical Isolates, Including Heteroresistant Enterobacter cloacae and Acinetobacter baumannii Strains , 2007, Antimicrobial Agents and Chemotherapy.
[114] J. Ferguson,et al. Cure of multiresistant Acinetobacter baumannii central nervous system infections with intraventricular or intrathecal colistin: case series and literature review. , 2006, The Journal of antimicrobial chemotherapy.
[115] E. Alp,et al. Acinetobacter baumannii meningitis in post-neurosurgical patients: clinical outcome and impact of carbapenem resistance. , 2007, The Journal of antimicrobial chemotherapy.
[116] J. Low,et al. Nebulized colistin in the treatment of pneumonia due to multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[117] J. Turnidge,et al. Comparison of once-, twice- and thrice-daily dosing of colistin on antibacterial effect and emergence of resistance: studies with Pseudomonas aeruginosa in an in vitro pharmacodynamic model. , 2008, The Journal of antimicrobial chemotherapy.
[118] R. Ostenson,et al. Polymyxin B and Rifampin: New Regimen for Multiresistant Serratia marcescens Infections , 1977, Antimicrobial Agents and Chemotherapy.
[119] S. Hammer,et al. Combination therapy with polymyxin B for the treatment of multidrug-resistant Gram-negative respiratory tract infections. , 2004, The Journal of antimicrobial chemotherapy.
[120] H. Marsh,et al. Using intrathecal colistin for multidrug resistant shunt infection , 2005, British journal of neurosurgery.
[121] J. Biehl,et al. Polymyxin B therapy of meningitis following procedures on central nervous system; beneficial therapeutic effect of polymyxin B in meningitis due to organisms of the colon group. , 1954, A.M.A. archives of internal medicine.
[122] A. Ketcham,et al. Pseudomonas meningitis complicating radical resection for radiorecurrent cancer of the paranasal sinuses: Report of two patients successfully treated with intrathecal polymyxin , 1973, Journal of surgical oncology.
[123] J. Turnidge,et al. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. , 2006, The Lancet. Infectious diseases.
[124] N. Høiby,et al. Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection. , 1987, The Journal of antimicrobial chemotherapy.
[125] R. Hancock,et al. Evidence for two distinct mechanisms of resistance to polymyxin B in Pseudomonas aeruginosa , 1984, Antimicrobial Agents and Chemotherapy.
[126] K. Ko,et al. High rates of resistance to colistin and polymyxin B in subgroups of Acinetobacter baumannii isolates from Korea. , 2007, The Journal of antimicrobial chemotherapy.
[127] H. Kallel,et al. Colistin as a salvage therapy for nosocomial infections caused by multidrug-resistant bacteria in the ICU. , 2006, International journal of antimicrobial agents.
[128] L. B. Hovde,et al. Colistin Methanesulfonate against Multidrug-Resistant Acinetobacter baumannii in an In Vitro Pharmacodynamic Model , 2007, Antimicrobial Agents and Chemotherapy.
[129] P. Hoeprich. The polymyxins. , 1970, The Medical clinics of North America.
[130] M. Falagas,et al. Cure of post-traumatic recurrent multiresistant Gram-negative rod meningitis with intraventricular colistin. , 2005, The Journal of infection.
[131] J. Turnidge,et al. Use of High-Performance Liquid Chromatography To Study the Pharmacokinetics of Colistin Sulfate in Rats following Intravenous Administration , 2003, Antimicrobial Agents and Chemotherapy.
[132] M. Falagas,et al. Colistin treatment in patients with ICU-acquired infections caused by multiresistant Gram-negative bacteria: the renaissance of an old antibiotic. , 2005, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[133] J. Leonard,et al. Sulfamethoxazole-Trimethoprim-Polymyxin Therapy of Serious Multiply Drug-Resistant Serratia Infections , 1976, Antimicrobial Agents and Chemotherapy.
[134] P. Quie,et al. Evaluation of the Bauer-Kirby-Sherris-Turck single-disc diffusion method of antibiotic susceptibility testing. , 1969, Antimicrobial agents and chemotherapy.
[135] R. Hancock,et al. Alteration of susceptibility to EDTA, polymyxin B and gentamicin in Pseudomonas aeruginosa by divalent cation regulation of outer membrane protein H1. , 1983, Journal of general microbiology.
[136] J. Li,et al. Old polymyxins are back: is resistance close? , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[137] G. Amsden. Tables of Antimicrobial Agent Pharmacology , 2010 .
[138] S. Shoham,et al. Amikacin and colistin for treatment of Acinetobacter baumannii meningitis. , 2005, The Journal of infection.
[139] A. Gales,et al. In vitro susceptibility of Stenotrophomonas maltophilia isolates: comparison of disc diffusion, Etest and agar dilution methods. , 2004, The Journal of antimicrobial chemotherapy.
[140] J. Garnacho-Montero,et al. Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[141] S. Hase,et al. The chemical structure of the lipid A component of lipopolysaccharides from Chromobacterium violaceum NCTC 9694. , 1977, European journal of biochemistry.
[142] D. Hamer. Treatment of nosocomial pneumonia and tracheobronchitis caused by multidrug-resistant Pseudomonas aeruginosa with aerosolized colistin. , 2000, American journal of respiratory and critical care medicine.
[143] H. E. Gilleland,et al. Chemical alterations in cell envelopes of polymyxin-resistant Pseudomonas aeruginosa isolates , 1979, Journal of bacteriology.
[144] G. Brownlee,et al. ‘Aerosporin’, an Antibiotic Produced by Bacillus aerosporus Greer , 1947, Nature.
[145] R. Stern,et al. The Pharmacokinetics of Colistin in Patients with Cystic Fibrosis , 2001, Journal of clinical pharmacology.
[146] A. Cox,et al. Ionizing groups in lipopolysaccharides of Pseudomonas cepacia in relation to antibiotic resistance , 1991, Molecular microbiology.
[147] H. Marsden,et al. COLISTIN METHANE SULPHONATE IN CHILDHOOD INFECTIONS , 1962 .
[148] G. W. Scott,et al. Pseudomonas pyocyanea infection treated with colistin methane sulphonate. , 1962, Lancet.
[149] M. Falagas,et al. Combination Therapy with Intravenous Colistin for Management of Infections Due to Multidrug-Resistant Gram-Negative Bacteria in Patients without Cystic Fibrosis , 2005, Antimicrobial Agents and Chemotherapy.
[150] A. Di Martino,et al. Intrathecal Use of Colistin , 2000, Journal of Clinical Microbiology.
[151] H. Mayer,et al. 4-Amino-4-deoxy-L-arabinose in LPS of enterobacterial R-mutants and its possible role for their polymyxin reactivity. , 1994, FEMS immunology and medical microbiology.
[152] J. Sarria,et al. Use of Intravenous Polymyxin B During Continuous Venovenous Hemodialysis , 2004, European Journal of Clinical Microbiology and Infectious Diseases.
[153] T. Yokochi,et al. Increased Phosphodiesters in Lipopolysaccharide Prepared from the Polymyxin B‐Resistant Isolate of Klebsiella pneumoniae , 1994, Microbiology and immunology.
[154] M. Miller,et al. NEBULISED COLOMYCIN FOR EARLY PSEUDOMONAS COLONISATION IN CYSTIC FIBROSIS , 1985, The Lancet.
[155] E. Giamarellos‐Bourboulis,et al. Interactions of colistin and rifampin on multidrug-resistant Acinetobacter baumannii. , 2001, Diagnostic microbiology and infectious disease.
[156] F. Rossi,et al. Annals of Clinical Microbiology and Antimicrobials Comparison of Disc Diffusion, Etest and Broth Microdilution for Testing Susceptibility of Carbapenem-resistant P. Aeruginosa to Polymyxins , 2022 .
[157] K. Dickinson,et al. A TRIAL OF COLISTIN METHANE SULPHONATE IN URINARY INFECTION WITH: Pseudomonas pyocyanea , 1962 .
[158] J. Łukasiak,et al. Efficacy of Tachyplesin III, Colistin, and Imipenem against a Multiresistant Pseudomonas aeruginosa Strain , 2007, Antimicrobial Agents and Chemotherapy.
[159] L. B. Hovde,et al. Synergistic Activity of Colistin and Ceftazidime against Multiantibiotic-Resistant Pseudomonas aeruginosa in an In Vitro Pharmacodynamic Model , 2003, Antimicrobial Agents and Chemotherapy.
[160] M. Wootton,et al. Safety and Tolerability of Bolus Intravenous Colistin in Acute Respiratory Exacerbations in Adults with Cystic Fibrosis , 2000, The Annals of pharmacotherapy.
[161] G. Shand,et al. Outer membrane proteins of polymyxin resistant Pseudomonas aeruginosa: effect of magnesium depletion. , 1988, The Journal of antimicrobial chemotherapy.
[162] S. Mubareka,et al. Aerosolized colistin for the treatment of nosocomial pneumonia due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis , 2005, Critical care.
[163] H. Al-Abdely,et al. Treatment of nosocomial meningitis due to a multidrug resistant Acinetobacter baumannii with intraventricular colistin. , 2005, Saudi medical journal.
[164] J. Heesemann,et al. Pitfalls of polymyxin antimicrobial susceptibility testing of Pseudomonas aeruginosa isolated from cystic fibrosis patients. , 2004, The Journal of antimicrobial chemotherapy.
[165] G. Turett,et al. Polymyxin B Nephrotoxicity and Efficacy against Nosocomial Infections Caused by Multiresistant Gram-Negative Bacteria , 2003, Antimicrobial Agents and Chemotherapy.